Aims: Low-grade ovarian endometrioid carcinomas may be associated with high-grade components. Whether the latter are clonally related to and originate from the low-grade endometrioid carcinoma remains unclear. The aim of this study was to use massively parallel sequencing to characterize the genomic landscape and clonal relatedness of an ovarian endometrioid carcinoma containing low-grade and high-grade components. Methods and results: DNA samples extracted from each tumour component (low-grade endometrioid, high-grade anaplastic and high-grade squamous) and matched normal tissue were subjected to targeted massively parallel sequencing with the 410-gene Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing assay. Somatic single nucleotide variants, small insertions and deletions, and copy number alterations were detected with state-of-the-art bioinformatics algorithms, and validated with orthogonal methods. The endometrioid carcinoma and the associated high-grade components shared copy number alterations and four clonal mutations, including SMARCA4 mutations, which resulted in loss of BRG1 protein expression. Subclonal mutations and mutations restricted to single components were also identified, such as distinct TP53 mutations restricted to each histological component. Conclusions: Histologically distinct components of ovarian endometrioid carcinomas may show intratumour genetic heterogeneity but be clonally related, harbouring a complex clonal composition. In the present case, SMARCA4 mutations were probably early events, whereas TP53 somatic mutations were acquired later in evolution.
Introduction
Ovarian endometrioid carcinomas (OECs) constitute 10-15% of ovarian carcinomas, 1 and closely resemble their uterine counterparts, being mostly low-grade, with frequent squamous differentiation, and unusual morphological patterns such as mucinous differentiation. 2, 3 High-grade OECs are relatively uncommon, 3 and their repertoire of somatic genetic alterations has yet to be fully characterized. 4 Rarer is the coexistence of low-grade and high-grade areas within OECs. 5 Massively parallel sequencing has revealed the phenomenon of intratumour genetic heterogeneity in cancer, 6 which may correlate with histological heterogeneity. 7 Here, we analysed a case of a lowgrade OEC with mucinous differentiation and histologically distinct high-grade components to define their repertoire of somatic genetic alterations, their clonal relatedness, and whether the low-grade OEC constituted the substrate from which the high-grade components originated.
Materials and methods
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After approval from the local Institutional Review Board and written informed consent from the patient had been obtained, the case was retrieved from the Department of Pathology, Rochester General Hospital, and histologically characterized on the basis of World Health Organization criteria. 1 The details of the immunohistochemical analysis (Table S1 ) and ERBB2 (HER2) dual-colour fluorescence in situ hybridization (FISH) 8 are given in Doc. S1.
T A R G E T E D C A P T U R E M A S S I V E L
DNA samples extracted from histologically distinct tumour components, separately microdissected as previously described, 7 and from normal tissue were subjected to targeted massively parallel sequencing using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay (410 key cancer genes), as previously described. 9, 10 Bioinformatics analyses for the identification of somatic mutations, their potential functional effect, copy number alterations (CNAs), cancer cell fractions, and mutational signatures, 9, [11] [12] [13] [14] [15] [16] [17] and for assessing clonal relatedness, 9 were performed as previously described (Doc. S1). 9 Sequencing data were deposited in the NCBI Sequence Read Archive, under accession code SRP059543. Selected somatic mutations identified by MSK-IMPACT sequencing and restricted to one or two of the tumour components (n = 64) were validated with high-depth targeted amplicon resequencing (Table S2) , and confirmed the accuracy of the MSK-IMPACT results, with a validation rate of 98.7%. 9, 11, 12, 18 Sanger sequencing was employed to investigate the presence of hotspot somatic mutations of POLD1, as previously described 18 (Doc. S1; Table S3 ).
Results
C A S E P R E S E N T A T I O N
A 68 year-old female presented with a left complex solid-cystic ovarian mass, measuring 200 9 150 mm. Histologically, the tumour was a grade 1 endometrioid carcinoma with mucinous differentiation and microscopically discrete foci of high-grade anaplastic carcinoma with rhabdoid/undifferentiated features, highgrade squamous cell carcinoma and spindle cell sarcoma-like areas ( Figure 1A ). The tumour stage was pT1aN0. The patient did not receive adjuvant chemotherapy or radiotherapy, and is currently without evidence of disease 28 months after diagnosis.
R E P E R T O I R E O F S O M A T I C G E N E T I C A L T E R A T I O N S
Whereas the reactive sarcoma-like component lacked CNAs and probably constituted reactive stroma, the low-grade endometrioid carcinoma and high-grade anaplastic and squamous cell carcinomas showed relatively simple genomes but shared focal similar CNAs (Figures 1B, S1 ; Table S4 ), including 17p losses and 17q gains. Amplification of 17q, encompassing the ERBB2 locus, was identified in the endometrioid carcinoma, whereas the anaplastic carcinoma and squamous cell carcinoma harboured gains of 17q ( Figures 1B, S1 ). FISH analysis validated these CNAs, but revealed heterogeneous ERBB2 amplification across components, characterized by an anatomically distinct amplified tumour population within the endometrioid carcinoma, and by admixed amplified and non-amplified cells in the anaplastic and squamous cell carcinomas ( Figure 1C ). MSK-IMPACT yielded a median depth of coverage of 4259 (range 4099 to 5369; Table S5 ) and, at variance with CNAs, revealed a high mutation burden. In total, we identified 101 non-synonymous somatic mutations affecting 69 genes, 39 of which were pathogenic or potentially pathogenic mutations (Figures 2A, S2 ; Table S6 ). No mutations were found in the sarcoma-like area, confirming its probable nonneoplastic nature.
Given the high mutation load, we sought to define whether this case harboured genetic alterations consistent with a mutator phenotype. 19 A clonal somatic missense POLE mutation (E349K) was identified by MSK-IMPACT in both high-grade carcinoma components; however, it did not target a hotspot, and was predicted to be non-pathogenic. POLD1 somatic hotspot mutations were not identified by Sanger sequencing (data not shown). All carcinomas retained MSH2, MSH6, MLH1 and PMS2 immunohistochemical expression, indicating DNA mismatch repair (MMR) proficiency ( Figure S3 ). Furthermore, germline hereditary cancer gene testing (Myriad myRisk), including MMR genes, revealed no mutations (data not shown). Given the lack of evidence of a hyper-mutator or ultramutator phenotype, we investigated the mutational signatures that shaped the genomes of the histologically distinct components. 20 All samples harbouring somatic mutations showed mutational signature 2 ( Figure 2B ), which has been linked to tumours with a analysis in an ovarian endometrioid carcinoma with mucinous differentiation and associated high-grade anaplastic carcinoma, squamous cell carcinoma and sarcoma-like components. A, Representative micrographs (haematoxylin and eosin) of low-grade endometrioid carcinoma with mucinous differentiation and high-grade anaplastic carcinoma, high-grade squamous cell carcinoma and reactive sarcoma-like components. B, Copy number alterations detected in the histologically distinct components of the tumour. Chromosomes are represented on the yaxis, with gains (light blue), losses (salmon), amplifications (dark blue) and homozygous deletions (dark red) plotted according to their respective genomic locations. C, FISH analysis for ERBB2 in the histologically distinct components using dual-colour probes for ERBB2 (red) and reference chromosome 17 (CEN, green). Note that the endometrioid carcinoma component, albeit considered to be ERBB2-amplified according to the American Society of Clinical Oncologists/College of American Pathologists guidelines, 35 showed a heterogeneous distribution of ERBB2 amplification (anatomically distinct amplified population, mean ERBB2 absolute number of 5.5, ERBB2/CEN17 ratio of 2.6; non-amplified population, mean ERBB2 absolute number of 1.6, ERBB2/CEN17 ratio of 1.6), whereas the anaplastic (mean ERBB2 absolute number of 5.7, ERBB2/CEN17 ratio of 1.5) and squamous cell carcinoma (mean ERBB2 absolute number of 4.6, ERBB2/CEN17 ratio of 1.8) components harboured ERBB2-amplified neoplastic cells (48% and 26% of cells with six or more ERBB2 copies, respectively) intermingled with neoplastic cells lacking ERBB2 amplification. The reactive sarcoma-like components showed diploid ERBB2 status (mean ERBB2 absolute number of 1.7, ERBB2/CEN17 ratio of 1.1).
high mutation burden and is associated with APOBEC cytidine deaminase activity. No somatic mutations or CNAs affecting APOBEC family genes were detected in the samples analysed.
In agreement with the CNA analysis, the carcinoma components shared nine identical somatic mutations. Four of these shared mutations were clonal (i.e. estimated by ABSOLUTE 21 Table S6 ), suggesting early biallelic inactivation of SMARCA4. Indeed, immunohistochemistry revealed lack of expression of BRG1, the protein product of SMARCA4, in all carcinoma components ( Figure 2C ).
Of the 101 non-synonymous mutations identified, 9%, 12% and 52% were restricted to the squamous cell, anaplastic and endometrioid carcinomas, respectively, and some of these may contribute to the distinct phenotype of each specific component of this case (Figures 2A, S2 ; Table S6 ). Nineteen mutations were shared solely by the high-grade squamous cell and anaplastic carcinoma components, including probably pathogenic mutations affecting CDKN2A, PTEN, PIK3R1 and APC. Consistent with these findings, PTEN protein expression was detected in the endometrioid carcinoma, whereas it was markedly reduced in the anaplastic and squamous cell carcinoma components ( Figure 2C ). TP53 was inactivated in the endometrioid, anaplastic and squamous cell carcinoma components by distinct clonal somatic mutations (E180K, Q331*, and E285K, respectively), all coupled with loss of heterozygosity of the wild-type allele ( Figure 2A ; Table S6 ), providing evidence of convergent evolution. 22 As expected, 23 the two missense mutations present in the endometrioid and squamous cell carcinomas resulted in p53 overexpression, whereas the truncating mutation in the anaplastic carcinoma resulted in weak patchy p53 expression ( Figure 2C ).
C L O N A L R E L A T E D N E S S A N D D E C O M P O S I T I O N
A formal clonal relatedness analysis based on all somatic mutations demonstrated that the endometrioid, anaplastic and squamous cell carcinoma components were clonally related (P < 0.05; Figure S4 ). Given the clonal nature of the components, we next performed a clonal decomposition analysis ( Figure 2D ), which suggested that SMARCA4 mutations were among the earliest genetic events. The endometrioid carcinoma evolved separately with the acquisition of clonal mutations affecting CDK12, MLH1, and MAPK1, whereas the anaplastic and squamous cell carcinomas stemmed from a common ancestor, sharing several clonal mutations, including those affecting CDKN2A, POLE, and ERBB2. TP53 mutations and ERBB2 amplification were probably later events in the tumour evolution.
Discussion
Coexisting low-grade OEC and high-grade carcinoma components may be clonally related and show complex clonal architecture, with substantial intratumour heterogeneity. In the present case, biallelic inactivation of SMARCA4 associated with lack of BRG1 expression was a truncal genetic event, potentially driving its early development. Both subclonal alterations and mutations restricted to one or two components were identified. The presence of unique TP53 somatic mutations and subclonal heterogeneous ERBB2 amplification in the different components suggests clonal evolution and convergent evolution 22 in the progression to the histologically distinct carcinoma components.
SMARCA4 encodes BRG1, a catalytic unit of the ATP-dependent switching and sucrose non-fermenting (SWI/SNF) chromatin regulators complex, which is frequently mutated in human malignancies. 24, 25 Somatic and germline SMARCA4 mutations underpin a panoply of carcinomas, often showing a rhabdoid phenotype, 26 such as ovarian small-cell carcinoma, hypercalcaemic type, [26] [27] [28] [29] and the undifferentiated components of dedifferentiated endometrial carcinomas. 30, 31 Our observation of biallelic inactivation of SMARCA4 in this case illustrates that loss of function of this gene is not necessarily restricted to tumours with a rhabdoid phenotype.
The marked morphological heterogeneity and high mutational burden of the case presented herein are reminiscent of those observed in POLE ultra-mutated or DNA MMR-deficient hyper-mutated endometrial carcinomas. 32, 33 This case, however, harboured neither DNA MMR alterations nor POLD1 or POLE hotspot mutations. Rather, enrichment for mutations consistent with the action of APOBEC cytidine deaminases was detected. Importantly, however, loss of SMARCA4 function has been linked to genetic instability and a high mutational burden, 34 and may provide another basis for the high mutational load and genetic and morphological intratumour heterogeneity observed in the present case.
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Loss of heterozygosity Cancer cell fraction CCF = 0% 0% < CCF < 5% 5% < CCF ≤ 20% 20% < CCF ≤ 40% 40% < CCF ≤ 60% 60% < CCF ≤ 80% 80% < CCF < 100% In conclusion, our study has revealed that intratumour histological heterogeneity in an OEC may be underpinned by, or at least coincidental with, genetic heterogeneity. The unusual high-grade histological components were, however, clonally related to the low-grade OEC, and the genetic alterations detected are consistent with convergent evolution in the progression of this tumour. Finally, our findings warrant further investigation of the role of chromatinremodelling genes in the development of genetically unstable low-grade OEC undergoing progression to high-grade carcinomas. Figure 2 . Repertoire of non-synonymous somatic mutations, mutational signatures and clonal decomposition of the ovarian endometrioid carcinoma with mucinous differentiation and anaplastic carcinoma and squamous cell carcinoma components. A, Heatmap depicting the cancer cell fractions of the somatic single nucleotide variants (SNVs) identified in each component. Each column represents one sample; mutations are reported in rows. The cancer cell fraction and clonality of the mutations were defined by ABSOLUTE. 21 Note that no somatic mutations were detected in the sarcoma-like component. B, Barplots illustrating the mutational signatures of all somatic SNVs of a given histological component according to the 96 substitution classification defined by the substitution classes (i.e. C>A, C>G, C>T, T>A, T>C and T>G bins), and the 5 0 and 3 0 sequence context. The heights of coloured bars represent the normalized fraction of mutations attributed to each of the 96 sub-bins. The pie charts show the mutational signatures present in a given component, and the sizes of the pie slices are proportional to the normalized fraction of the mutation types (i.e. C>A, C>G, C>T, T>A, T>C, and T>G). 9 C, Representative micrographs of BRG1, p53 and PTEN expression in the endometrioid carcinoma, anaplastic carcinoma component, and squamous cell carcinoma component. Loss of BRG1 expression is seen in the three components (lymphocytes and stromal cells serve as internal positive controls); the p53 expression pattern differs between tumour components, consistent with their distinct private TP53 mutations; PTEN expression is retained in the endometrioid carcinoma areas, whereas the anaplastic carcinoma and squamous cell carcinoma components show marked reductions in PTEN expression. D, Phylogenetic tree depicting the clonal evolution of the different histological components. The length of each branch is proportional to the number of mutations that distinguish a given clone from its ancestral clone, and selected somatic mutations that define a given clone are shown. AC, anaplastic carcinoma component; CCF, cancer cell fraction; OEC, ovarian endometrioid carcinoma; SCC, squamous cell carcinoma component.
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